AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
buformin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antihyperglycaemics, phenformin derivatives | 423 | 692-13-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 1.84 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 6.58 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.90 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 4.62 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,CHUK,CSF1R,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FGFR1,FLT1,FLT3,GRK2,GSK3B,IGF1R,IKBKB,ITK,JAK1,JAK2,JAK3,KIT,MAP2K1,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK12,MAPK14,MAPK7,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 | 76 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AXL,CAMK2D,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,GRK2,MAP3K21,MAPK7,SIK2,STK33,TEK | 16 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10BA03 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Biguanides |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:132992 | radiosensitizing agent |
| CHEBI has role | CHEBI:176497 | geroprotector |
| MeSH PA | D007004 | Hypoglycemic Agents |
Related Drugs by ATC class:
A10BA Biguanides 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.6 | Basic |
| pKa2 | 3.6 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D00595 | KEGG_DRUG |
| C0006359 | UMLSCUI |
| CHEBI:3209 | CHEBI |
| BFR | PDB_CHEM_ID |
| CHEMBL39736 | ChEMBL_ID |
| DB04830 | DRUGBANK_ID |
| D002026 | MESH_DESCRIPTOR_UI |
| 2468 | PUBCHEM_CID |
| 2004 | INN_ID |
| W2115E9C7B | UNII |
| 1190-53-0 | SECONDARY_CAS_RN |
Pharmaceutical products:
None